41 results
PX14A6G
REGN
Regeneron Pharmaceuticals, Inc.
18 May 23
Letter to shareholders
4:46pm
exclusivity periods gained from secondary patents, and the resulting delay in generic entry, limit patient access, create regulatory and reputational risk
DEFA14A
hcljdmb20tljaaz4s4t6
21 Apr 22
Additional proxy soliciting materials
4:21pm